

VIRGINIA COMMONWEALTH UNIVERSITY

School of Engineering GO VIRGINIA

Barbara D. Boyan, PhD Dean and Alice T. and William H. Goodwin Chair

August 23, 2016

Engineering and Economic Development

•Engineering bridges scientific advances into technical capabilities and workforce development that are essential to drive sustainable economic growth.

•US capacity and capability to maintain globallycompetitive standing is constantly challenged.

We are building processes to accelerate innovation and improve commercialization success

while

Educating students and attracting leaders to the region.



Partnerships are Essential

• Support Basic Research

Need effective Government – Academic – Industry collaboration.

- Affect Translational Research Success
 Must increase level of industry- sponsored
 research for effective commercialization.
- Build Competitive Infrastructure

Share across all sectors.

Workforce education & development required across society.



Case Study: Pharmaceutical Engineering

- Healthcare is 18% of US GDP; pharmaceuticals are an ever increasing proportion.
- U.S. leads in clinical development, but has outsourced most value-added manufacturing.
- Opportunities exist to radically change how drugs are manufactured, distributed and used.

REDUCE COST, IMPROVE ACCESS, IMPROVE EFFECTIVENESS



Pharmaceutical Engineering Driving Economic Growth

- Opportunity to be the best, not just first
- Rapid, demonstrated success
 - Great partnerships
 - Great Infrastructure
- Projects underway
 - Bill and Melinda Gates Foundation "Optimization Programs"
 - DARPA: Drugs on Demand
 - NSF IUCRC on Catalysis
 - Industry Projects
 - Additive Manufacturing Opportunities
 - New Enabling Technologies (Catalysts, Sensors)


This Program Did Not Exist Three Years Ago





VCU Pharmaceutical Engineering

Chairman and Founder: Dr. Frank Gupton Director: Dr. Tom Roper



School of Engineering

IRGINIA COMMONWEALTH UNIVERSITY

Gates Foundation Program

Specific High-Value Deliverables: Optimize Manufacturing Processes to Improve Patient Access; Provide Value for Multiple Stakeholders.

New Drug Development	Pretomanid Tafenoquine Dolutegravir	Patients Improve Access to
	Isonaizid	Lifesaving Drugs Health
High Volume Drugs	Efavirenz Lamivudine Nevirapine Tenofovir	Providers
	Zidovudine Darunavir	Improve Supplier Economics in
Low Volume Drugs	Atazanavir Emtricitabine Ritonavir	Developing Markets New Generics
	Abacavir	

UN


School of Engineering

"Medicines For All" Inter-relationships

Leverages organizational competencies to ensure benefits are realized through the supply chain and distribution to patients.

- Drug Target
 Identification
 Priorities established
 - by Sponsors.
- Drug Transformation VCU research unlocks the economic potential.
- Manufacturing & Market Distribution
 VCU collaborates with
 NGOs &

manufacturers to facilitate rapid commercialization.



VCU now expanding to US – based Sponsors and Manufacturers.



Conclusion

- *Proven, scalable model* to bring improvements to global healthcare.
- Sponsor support (Gates Foundation) provides capital and market interface and leverage.
- Organizational infrastructure creates a permanent, sustainable networking model and provides an educational vehicle for future engineers.





Using Existing Competencies to Drive New Economic Opportunity

- Industry Partnerships: Develop Pharmaceutical Manufacturing Technology Cluster
- NewCo (Tech Spin-Outs): New Pharma Co's
- Enabling Technology Opportunity
 - Continuous Flow Manufacture, Sensors

Create New Linkages and New Clusters

- Additive Manufacture of Pharmaceuticals (with CCAM)
- Regulatory Optimization Opportunities
- Re-Invent Distribution and Logistics for the Pharmaceutical Industry (with CCALS)



Economic Development Infrastructure: Engineering Research Building at VCU







VIRGINIA COMMONWEALTH UNIVERSITY

School of Engineering